17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
17α,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters having remarkable antiandrogenic activity are provided, along with methods of using these compounds and processes for their preparation.
1. A pharmaceutical formulation for the treatment of acne, alopecia, hirsutism, or seborrhea, the formulation comprising an effective amount of 17α-propionyloxy-21-hydroxy-pregna-4-ene-3,20-dione, wherein the formulation is suitable for topical application, and wherein the formulation comprises a pharmaceutically acceptable carrier.
2. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation is in the form of a cream.
3. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation is in the form of a gel.
4. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation is in the form of a liposomal emulsion or suspension.
5. The pharmaceutical formulation of claim 2 , wherein the cream comprises at least one excipient selected from the group consisting of cetyl alcohol, glycerol monostearate, liquid paraffin, propylene glycol, disodium mono-oleo-amide sulfosuccinate, citric acid monohydrate, and water.
6. The pharmaceutical formulation of claim 5 , wherein the cream comprises cetyl alcohol.
7. The pharmaceutical formulation of claim 6 , wherein the cream further comprises glycerol monostearate.
8. The pharmaceutical formulation of claim 7 , wherein the cream further comprises liquid paraffin.
9. The pharmaceutical formulation of claim 8 , wherein the cream further comprises propylene glycol.
10. The pharmaceutical formulation of claim 9 , wherein the cream further comprises disodium mono-oleo-amide sulfosuccinate.
11. The pharmaceutical formulation of claim 10 , wherein the cream further comprises citric acid monohydrate.
12. The pharmaceutical formulation of claim 11 , wherein the cream further comprises water.
13. A method of treating hirsutism, the method comprising administering to a patient in need thereof an effective amount of 17α-propionyloxy-21-hydroxy-pregna-4-ene-3,20-dione.
14. The method of claim 13 , wherein the 17α-propionyloxy-21-hydroxy-pregna-4-ene-3,20-dione is applied topically.
15. The method of claim 13 , wherein the 17α-propionyloxy-21-hydroxy-pregna-4-ene-3,20-dione is present in a pharmaceutical formulation suitable for topical application.
16. The method of claim 15 , wherein the pharmaceutical formulation comprises a pharmaceutically acceptable carrier.
17. The method of claim 15 , wherein the pharmaceutical formulation is in the form of a cream.
18. The method of claim 15 , wherein the pharmaceutical formulation is in the form of a gel.
19. The method of claim 15 , wherein the pharmaceutical formulation is in the form of a liposomal emulsion or suspension.
20. A method of treating seborrhea, the method comprising administering to a patient in need thereof an effective amount of 17α-propionyloxy-21-hydroxy-pregna-4-ene-3,20-dione.
21. The method of claim 20 , wherein the 17α-propionyloxy-21-hydroxy-pregna-4-ene-3,20-dione is applied topically.
22. The method of claim 21 , wherein the 17α-propionyloxy-21-hydroxy-pregna-4-ene-3,20-dione is present in a pharmaceutical formulation suitable for topical application.
23. The method of claim 22 , wherein the pharmaceutical formulation comprises a pharmaceutically acceptable carrier.
24. The method of claim 22 , wherein the pharmaceutical formulation is in the form of a cream.
25. The method of claim 22 , wherein the pharmaceutical formulation is in the form of a gel.
26. The method of claim 22 , wherein the pharmaceutical formulation is in the form of a liposomal emulsion or suspension.